The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...

One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime. For many, the diagnosis doesn’t end there — up to 30 percent of early-stage breast cancer cases will later ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Now, if ever there ...

Hormone therapy for ER-positive/HER2-negative metastatic breast cancer involves CDK4/6 inhibitors and aromatase inhibitors or fulvestrant to control disease ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for gedatolisib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA ...

When you get an HR+/HER2- metastatic breast cancer (MBC) diagnosis, it can feel like your future is out of your hands. Treatment for this type of cancer targets certain receptors on cancer cells, and ...

The novel oral selective estrogen receptor (ER) degrader giredestrant significantly reduced the risk of invasive disease ...

This symposium took place during the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The aim ...

Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...

Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial. This is an ASCO Meeting Abstract from the ...